Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 12/20 | 0.44 |
| ▸ | CA1 | P00915 | 12/20 | 0.44 |
| ▸ | CA2 | P00918 | 12/20 | 0.44 |
| ▸ | CA4 | P22748 | 11/20 | 0.44 |
| ▸ | CA5A | P35218 | 11/20 | 0.44 |
| ▸ | CA7 | P43166 | 11/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 11/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | CA6 | P23280 | 4/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19415672 | 1.00 | TSHR (0.63) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL14248547 | 1.00 | TSHR (0.63) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL19415621 | 1.00 | TSHR (0.63) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL12601659 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL12334423 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL15368881 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL222652 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL12649999 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL2469148 | 0.90 | TSHR (0.64) | TSHRPTPN1CA12CA1CA2 | |
| SCHEMBL14081703 | 0.86 | TSHR (0.58) | TSHRPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2676965-B1 | ARYL GLYCOSIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2017-10-04 | — | — | EP | disclosed |
| EP-2755722-B1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2017-05-24 | — | — | EP | disclosed |
| US-9018249-B2 | SGLT inhibitors | PANACEA BIOTEC LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-8980829-B2 | Aryl glycoside compound, preparation method and use thereof | SHANGHAI YINGLI SCIENCE AND TECHNOLOGY CO., LTD (CN) | 2015-03-17 | — | — | US | disclosed |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| US-20140228303-A1 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD (IN) | 2014-08-14 | — | — | US | disclosed |
| EP-2755722-A2 | NOVEL SGLT INHIBITORS | Panacea Biotec Ltd. (IN) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038429-A2 | NOVEL SGLT INHIBITORS | PANACEA BIOTEC LTD. (IN) | 2013-03-21 | — | — | WO | disclosed |
| US-7858587-B2 | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858587-B2 | Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2074130-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1928852-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008034859-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008034859-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031548-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031548-A2 | PROCESSES FOR PREPARING OF GLUCOPYRANOSYL-SUBSTITUTED (ETHYNYL-BENZYL)-BENZENE DERIVATIVES AND INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228303-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | TSHR 3621/4885PTPN1 304/4885CA12 1479/4885 |
| US-20070073046-A1 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | UGGT1, B3GAT3, UGCG | TSHR 2756/4885PTPN1 2535/4885CA12 2407/4885 |
| US-20090318547-A1 | GLUCOPYRANOSYL-SUBSTITUTED DIFLUOROBENZYL-BENZENE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | UGGT1, SLC5A2, SLC5A1 | TSHR 2823/4885PTPN1 964/4885CA12 1576/4885 |
| US-20140378540-A1 | NOVEL SGLT INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | TSHR 3621/4885PTPN1 304/4885CA12 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.